EU regulators back Ipsen cancer drug in new liver cancer use

Ipsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed it in a new indication of second line liver cancer – a use whe

LEO Pharma acquires Bayer’s dermatology unit

Danish LEO Pharma announced yesterday (July 31st) that it has entered a binding agreement to purchase Bayer's global prescription dermatology portfolio, in line with its goal to help 125 mi

Bayer hits back at Netflix medical device documentary

Bayer has issued a robust defence of Essure after the birth control implant was featured in The Bleeding Edge, a Netflix documentary about the medical devices industry.

Eisai’s EMEA CEO Gary Hendler on why quality of life is key ...

Raising the bar in liver cancer therapy

Bayer and MD Anderson collaborate on novel targeted cancer t...

Bayer and the University of Texas MD Anderson Cancer Center have signed a five-year collaboration agreement to accelerate the development of novel targeted treatments for cancer.